ReviewSeminars in nuclear medicine2022
Total-body PET/CT - First Clinical Experiences and Future Perspectives.
Review in Seminars in nuclear medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 43 citations in OpenAlex.
- Optimizing acquisition time and injected dose inBMC medical informatics and decision making · 2026Article
- Modelling image quality over extended [Frontiers in oncology · 2026Article
- Long Axial Field-of-view PET: A New Era of Quantitative PET Imaging for Theranostic Applications in Clinic.PET clinics · 2025Review
- Recent advances in theranostics and oncology PET: emerging radionuclides and targets.Annals of nuclear medicine · 2025Review
- Total-body positron emission tomography imaging to accelerate radiotracer discovery pipelines.Pharmacological reviews · 2025Review
- Deep learning-based time-of-flight (ToF) enhancement of non-ToF PET scans for different radiotracers.European journal of nuclear medicine and molecular imaging · 2025Article
- Managing incidental findings in total body PET/CT studies: balancing ethical considerations and resource constraints.EJNMMI reports · 2025Article
- 18F-Sodium Fluoride PET/CT as a Tool to Assess Enthesopathies in X-Linked Hypophosphatemia.Calcified tissue international · 2025Article
- CombinedFrontiers in medicine · 2025Article
- Multimodal positron emission tomography (PET) imaging in non-oncologic musculoskeletal radiology.Skeletal radiology · 2024Review
- Artificial intelligence-based joint attenuation and scatter correction strategies for multi-tracer total-body PET.EJNMMI physics · 2024Article
- Data-driven gated positron emission tomography/computed tomography for radiotherapy.Physics and imaging in radiation oncology · 2024Review
- Spatial Atlas for Mapping Vascular Microcalcification Using 18F-NaF PET/CT: Application in Hyperphosphatemic Familial Tumoral Calcinosis.Arteriosclerosis, thrombosis, and vascular biology · 2024Article
- Performance and application of the total-body PET/CT scanner: a literature review.EJNMMI research · 2024Review
- Extracting value from total-body PET/CT image data - the emerging role of artificial intelligence.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Review
- Total-body PET/CT with half-dose [European journal of nuclear medicine and molecular imaging · 2024Article
- Characterisation of a novel [EJNMMI research · 2023Article
- Long axial field of view (LAFOV) PET-CT: implementation in static and dynamic oncological studies.European journal of nuclear medicine and molecular imaging · 2023Review
- Long-axial field-of-view PET/CT: perspectives and review of a revolutionary development in nuclear medicine based on clinical experience in over 7000 patients.Cancer imaging : the official publication of the International Cancer Imaging Society · 2023Review
- Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives.Biomarker research · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
Total-body PET has come a long way from its first conception to today, with both total-body and long axial field of view (> 1m) scanners now being commercially available world-wide. The conspicuous signal collection efficiency gain, coupled with high spatial resolution, allows for higher sensitivity and improved lesion detection, enhancing several clinical applications not readily available on current conventional PET/CT scanners. This technology can provide (a) reduction in acquisition times with preservation of diagnostic quality images, benefitting specific clinical situations (i.e. pediatric patients) and the use of several existing radiotracers that present transient uptake over time and where small differences in acquisition time can greatly impact interpretation of images; (b) reduction in administered activity with minimal impact on image noise, thus reducing effective dose to the patient, improving staff safety, and helping with logistical concerns for short-lived radionuclides or long-lived radionuclides with poor dosimetry profiles that have had limited use on conventional PET scanners until now; (c) delayed scanning, that has shown to increase the detection of even small and previously occult malignant lesions by improved clearance in regions of significant background activity and by reduced visibility of coexisting inflammatory processes; (d) improvement in image quality, as a consequence of higher spatial resolution and sensitivity of total-body scanners, implying better appreciation of small structures and clinical implications with downstream prognostic consequences for patients; (e) simultaneous total-body dynamic imaging, that allows the measurement of full spatiotemporal distribution of radiotracers, kinetic modeling, and creation of multiparametric images, providing physiologic and biologically relevant data of the entire body at the same time. On the other hand, the higher physical and clinical sensitivity of total-body scanners bring along some limitations and challenges. The strong impact on clinical sensitivity potentially increases the number of false positive findings if the radiologist does not recalibrate interpretation considering the new technique. Delayed scanning causes logistical issues and introduces new interpretation questions for radiologists. Data storage capacity, longer processing and reconstruction time issues are other limitations, but they may be overcome in the near future by advancements in reconstruction algorithms and computing hardware.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.